Drug of Choice for Hepatic Ascites
Spironolactone is the drug of choice for hepatic ascites, typically initiated at 100 mg daily, often combined with furosemide 40 mg daily in a 100:40 ratio to optimize natriuresis while maintaining normokalemia. 1
First-Line Diuretic Strategy
The most recent 2025 AGA guidelines and 2021 AASLD practice guidance consistently establish that combined spironolactone and furosemide therapy outperforms mineralocorticoid receptor antagonist monotherapy 1. This combination approach:
- Enhances natriuresis and diuresis more effectively than sequential therapy
- Maintains normokalemia (the 100:40 ratio prevents both hypokalemia from loop diuretics and hyperkalemia from aldosterone antagonists)
- Works faster than spironolactone alone in patients with established ascites
Dosing Algorithm
Initial therapy:
- Spironolactone 100 mg once daily (morning dose to avoid nocturia) 1
- Furosemide 40 mg once daily 1
- Sodium restriction to <2000 mg/day 1
Titration strategy:
- Adjust spironolactone in 100 mg increments up to 400 mg/day maximum 2
- Wait at least 72 hours between dose adjustments (due to spironolactone's long half-life) 2
- Adjust furosemide in increments up to 160 mg/day maximum 2
- Target weight loss: 0.5 kg/day without peripheral edema, 1 kg/day with edema 1
Clinical Context Matters
For first episode of ascites: The evidence shows spironolactone monotherapy generates adequate response with fewer side effects 2. You can start with spironolactone alone at 100 mg daily.
For long-standing or recurrent ascites: Combined therapy from the outset is superior 2. Start both drugs simultaneously.
For grade 3 (tense) ascites: Perform large-volume paracentesis first with albumin replacement, then initiate diuretics after reducing intra-abdominal pressure 2.
Important Caveats
Monitor closely for:
- Electrolyte abnormalities (20-40% of patients experience adverse effects) 2
- Renal function deterioration
- Hyponatremia (does NOT require fluid restriction unless significant) 1
- Painful gynecomastia from spironolactone (switch to amiloride or eplerenone if intolerable) 2
Avoid spironolactone in patients with:
- Pre-existing hyperkalemia
- Severe renal impairment (use higher loop diuretic doses with lower aldosterone antagonist doses) 2
Monitoring strategy:
- Daily weights by patient
- Spot urine sodium/potassium ratio: if >1, patient should be losing weight; if not, suspect dietary non-compliance 2
- If ratio ≤1, insufficient natriuresis—increase diuretics 2
Why Spironolactone is Superior
The pathophysiology of cirrhotic ascites involves secondary hyperaldosteronism driving sodium retention 1. Spironolactone directly antagonizes this mechanism at the mineralocorticoid receptor, addressing the root cause rather than just forcing diuresis. Loop diuretics alone fail to address the aldosterone-mediated sodium avidity and cause potassium wasting, making them inferior as monotherapy.
Once ascites is controlled, taper to the lowest effective maintenance dose to minimize side effects while preventing recurrence 2.